September 28, 2017 – Vancouver, BC –Isodiol International Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) (the “Company” or “Isodiol”) a global cannabis innovator specializing in the development of pharmaceutical and consumer products is pleased to announce the formation of IsoLabs International, a new division that will focus in the licensed medical marijuana markets in both North America and abroad. IsoLabs will process and manufacture medical cannabis products within approved jurisdictions.
The Company will further develop its current cannabinoid product line, which includes capsules, tinctures, transdermal patches, spray, oils, water and topicals, into a full spectrum offering with both whole plant extracts and THC-only products. Whole plant extracts is a term used to describe products that include THC, CBD and other natural cannabis derivatives. The company will continue to externally source the cultivation of the plant and bring the manufacturing, processing, product R&D and distribution in-house.
“The launch of IsoLabs is a significant milestone for the company,” said Marcos Agramont, CEO of Isodiol. “We have had a presence in hemp derived, non-THC pharmaceutical and nutraceutical space for many years where we pioneered some of the first hemp derived products and technologies in the market. This strategic entrance into the licensed medical marijuana market will further expand our existing product lines. Also, as we continue to navigate the legal landscape in the US and Canada, having the ability to vertically integrate our operations is extremely important, which will be a strategy consistent throughout our international expansion.”
Currently, IsoLabs is exploring opportunities in the California and Canadian markets. For more information on Isodiol, please visit Isodiol.com
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical and nutraceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of a 99%+ pure pharmaceutical grade cannabinoid crystalline isolate derived from exempt parts of the hemp plant, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
ON BEHALF OF THE BOARD
“Marcos Agramont” CEO & Director
Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation, and does not intend, to update any forward looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release.